ELPAMOTIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C47H76N16O13
Molecular Weight	1073.2057
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C(O)=O

InChI

InChIKey=ZAJHBCDPAUKEPU-GIKXZWSFSA-N

InChI=1S/C47H76N16O13/c1-5-25(4)37(45(75)76)62-40(70)28(15-10-18-55-47(52)53)58-41(71)30(21-33(49)64)57-34(65)23-56-39(69)31(22-35(66)67)60-43(73)32-16-11-19-63(32)44(74)36(24(2)3)61-42(72)29(20-26-12-7-6-8-13-26)59-38(68)27(48)14-9-17-54-46(50)51/h6-8,12-13,24-25,27-32,36-37H,5,9-11,14-23,48H2,1-4H3,(H2,49,64)(H,56,69)(H,57,65)(H,58,71)(H,59,68)(H,60,73)(H,61,72)(H,62,70)(H,66,67)(H,75,76)(H4,50,51,54)(H4,52,53,55)/t25-,27-,28-,29-,30-,31-,32-,36-,37-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C47H76N16O13
Molecular Weight	1073.2057
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22957712 | https://www.ncbi.nlm.nih.gov/pubmed/25867139 | https://www.ncbi.nlm.nih.gov/pubmed/25502982 | https://adisinsight.springer.com/drugs/800022791

Elpamotide is an anti-angiogenic cancer vaccine. It is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) (RFVPDGNRI) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. OncoTherapy Science was developing elpamotide for the treatment of solid tumors.

Originator

Approval Year

PubMed

Title	Date	PubMed
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.	2010 Feb	19930156
Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.	2012 Dec	22957712
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.	2015 Apr	25502982
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.	2015 Jul	25867139

Sample Use Guides

In Vivo Use Guide

phase II/III clinical trial for the treatment of pancreatic cancer: emulsified elpamotide (2.0 mg/mL/body) every week

Route of Administration:

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:39:51 GMT 2023` Edited by `admin` on `Sat Dec 16 01:39:51 GMT 2023`
Record UNII	S68632MB2G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ELPAMOTIDE

Official Name

English

elpamotide [INN]

Common Name

English

L-ARGINYL-L-PHENYLALANYL-L-VALYL-L-PROLYL-L-.ALPHA.-ASPARTYLGLYCYL-L-ASPARAGINYL-L-ARGINYL-L-ISOLEUCINE HUMAN SOLUBLE (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR) VEGFR2-(169-177)-PEPTIDE

Common Name

English

VEGFR2-169 PEPTIDE VACCINE

Common Name

English

ELPAMOTIDE [JAN]

Common Name

English

L-ISOLEUCINE, L-ARGINYL-L-PHENYLALANYL-L-VALYL-L-PROLYL-L-.ALPHA.-ASPARTYLGLYCYL-L-ASPARAGINYL-L-ARGINYL-

Common Name

English

VEGFR2-169

Code

English

Elpamotide [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1663